{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T13:09:50Z","timestamp":1780578590307,"version":"3.54.1"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:00:00Z","timestamp":1777507200000},"content-version":"vor","delay-in-days":2,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Ovarian clear cell carcinoma (OCCC) frequently exhibits resistance to conventional chemotherapy with limited treatment options. This study reports a heavily pretreated advanced case with liver metastases to investigate the efficacy of gemcitabine combined with PD-1 inhibitor in such refractory patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We present a case of stage IIIC OCCC that progressed after first-line platinum-based chemotherapy. The patient was treated with gemcitabine in combination with the PD-1 inhibitor toripalimab. Genetic alterations were analyzed using next-generation sequencing, and PD-L1 expression was assessed by immunohistochemistry (combined positive score [CPS]). Treatment response and safety profiles were regularly monitored.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The combination therapy induced a complete remission lasting over 24\u2009months, with a manageable safety profile. Molecular profiling revealed a loss-of-function mutation in ARID1A, which may enhance tumor sensitivity to gemcitabine, while elevated PD-L1 expression (CPS\u2009=\u200930) may serve as a predictive biomarker for immunotherapy response in OCCC. Notably, the deep and durable clinical response observed suggests a potential synergistic effect between gemcitabine and immunotherapy, wherein ARID1A deficiency-induced chemosensitivity may prime the tumor microenvironment for enhanced immune checkpoint inhibition, offering a compelling rationale for this combination strategy in platinum-resistant OCCC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study proposes a promising therapeutic strategy for advanced OCCC and supports the clinical value of molecular profiling-guided treatment. Both ARID1A status and PD-L1 expression warrant further validation as potential biomarkers in prospective clinical trials.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyag164","type":"journal-article","created":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T11:24:14Z","timestamp":1777289054000},"source":"Crossref","is-referenced-by-count":0,"title":["Durable response to chemoimmunotherapy in a patient with refractory metastatic ovarian clear cell carcinoma: a case report and literature review"],"prefix":"10.1093","volume":"31","author":[{"given":"Lili","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Gynecology, the First Affiliated Hospital of China Medical University , Shenyang, 110001,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyang","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Gynecology, the First Affiliated Hospital of China Medical University , Shenyang, 110001,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Gynecology, the First Affiliated Hospital of China Medical University , Shenyang, 110001,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Gynecology, the First Affiliated Hospital of China Medical University , Shenyang, 110001,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-4057-8415","authenticated-orcid":false,"given":"Xiangkai","family":"Meng","sequence":"additional","affiliation":[{"name":"Department of Gynecology, the First Affiliated Hospital of China Medical University , Shenyang, 110001,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,4,28]]},"reference":[{"key":"2026060408361613300_oyag164-B1","first-page":"649","article-title":"[Introduction of WHO classification of tumours of female reproductive organs, fourth edition]","volume":"43","author":"Lu","year":"2014","journal-title":"Zhonghua Bing Li Xue Za Zhi"},{"key":"2026060408361613300_oyag164-B2","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.semcancer.2019.10.025","article-title":"Translational genomics of ovarian clear cell carcinoma","volume":"61","author":"Khalique","year":"2020","journal-title":"Semin Cancer Biol"},{"key":"2026060408361613300_oyag164-B3","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1097\/PAT.0000000000000223","article-title":"Comparative analysis of Napsin A, alpha-methylacyl-coenzyme a racemase (AMACR, P504S), and hepatocyte nuclear factor 1 beta as diagnostic markers of ovarian clear cell carcinoma: an immunohistochemical study of 279 ovarian tumours","volume":"47","author":"Fadare","year":"2015","journal-title":"Pathology"},{"key":"2026060408361613300_oyag164-B4","first-page":"8305","article-title":"Diagnostic value of dual detection of hepatocyte nuclear factor 1 beta (HNF-1\u03b2) and napsin a for diagnosing ovarian clear cell carcinoma","volume":"8","author":"Li","year":"2015","journal-title":"Int J Clin Exp Pathol"},{"key":"2026060408361613300_oyag164-B5","doi-asserted-by":"publisher","first-page":"292","DOI":"10.48095\/ccko2024292","article-title":"The guidelines for clinical practice for carriers of germline mutations in hereditary breast, ovarian, prostate, and pancreatic cancer predisposition genes BRCA1, BRCA2, PALB2, ATM, and CHEK2 (4.2024)","volume":"37","author":"Kleiblov\u00e1","year":"2024","journal-title":"Klin Onkol"},{"key":"2026060408361613300_oyag164-B6","doi-asserted-by":"publisher","first-page":"6118","DOI":"10.1038\/ncomms7118","article-title":"Coexistent ARID1A-PIK3CA mutations promote ovarian clear-cell tumorigenesis through pro-tumorigenic inflammatory cytokine signalling","volume":"6","author":"Chandler","year":"2015","journal-title":"Nat Commun"},{"key":"2026060408361613300_oyag164-B7","doi-asserted-by":"publisher","first-page":"512","DOI":"10.6004\/jnccn.2024.0052","article-title":"NCCN guidelines\u00ae Insights: ovarian cancer\/fallopian tube cancer\/primary peritoneal cancer, version 3.2024","volume":"22","author":"Liu","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"key":"2026060408361613300_oyag164-B8","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.ygyno.2006.12.024","article-title":"Lack of effective systemic therapy for recurrent clear cell carcinoma of the ovary","volume":"105","author":"Crotzer","year":"2007","journal-title":"Gynecol Oncol"},{"key":"2026060408361613300_oyag164-B9","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1136\/ijgc-2019-000287","article-title":"Patterns of recurrence and impact on survival in patients with clear cell ovarian carcinoma","volume":"29","author":"Hogen","year":"2019","journal-title":"Int J Gynecol Cancer"},{"key":"2026060408361613300_oyag164-B10","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.7150\/jca.53395","article-title":"Updates of pathogenesis, diagnostic and therapeutic perspectives for ovarian clear cell carcinoma","volume":"12","author":"Zhu","year":"2021","journal-title":"J Cancer"},{"key":"2026060408361613300_oyag164-B11","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1158\/2159-8290.CD-17-0151","article-title":"AACR project GENIE: Powering precision medicine through an international consortium","volume":"7","year":"2017","journal-title":"Cancer Discov"},{"key":"2026060408361613300_oyag164-B12","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1126\/science.1196333","article-title":"Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma","volume":"330","author":"Jones","year":"2010","journal-title":"Science"},{"key":"2026060408361613300_oyag164-B13","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1056\/NEJMoa1008433","article-title":"ARID1A mutations in endometriosis-associated ovarian carcinomas","volume":"363","author":"Wiegand","year":"2010","journal-title":"N Engl J Med"},{"key":"2026060408361613300_oyag164-B14","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.ygyno.2019.10.002","article-title":"Therapeutic preferability of gemcitabine for ARID1A-deficient ovarian clear cell carcinoma","volume":"155","author":"Kuroda","year":"2019","journal-title":"Gynecol Oncol"},{"key":"2026060408361613300_oyag164-B15","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/s41591-018-0012-z","article-title":"ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade","volume":"24","author":"Shen","year":"2018","journal-title":"Nat Med"},{"key":"2026060408361613300_oyag164-B16","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-010069","article-title":"Genetic and therapeutic heterogeneity shape the baseline and longitudinal immune ecosystem of ovarian clear cell carcinoma","volume":"12","author":"Xia","year":"2024","journal-title":"J Immunother Cancer"},{"key":"2026060408361613300_oyag164-B17","doi-asserted-by":"publisher","first-page":"4032","DOI":"10.1158\/1078-0432.CCR-22-2176","article-title":"Facts and hopes in colorectal cancer immunotherapy","volume":"29","author":"Foote","year":"2023","journal-title":"Clin Cancer Res"},{"key":"2026060408361613300_oyag164-B18","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1016\/j.ccell.2024.03.002","article-title":"Impact of renal cell carcinoma molecular subtypes on immunotherapy and targeted therapy outcomes","volume":"42","author":"Saliby","year":"2024","journal-title":"Cancer Cell"},{"key":"2026060408361613300_oyag164-B19","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.eururo.2024.10.019","article-title":"First and second-line treatments in metastatic renal cell carcinoma","volume":"87","author":"Barragan-Carrillo","year":"2025","journal-title":"Eur Urol"},{"key":"2026060408361613300_oyag164-B20","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.ygyno.2024.03.027","article-title":"Phase II trial of pembrolizumab and epacadostat in recurrent clear cell carcinoma of the ovary: an NRG oncology study GY016","volume":"186","author":"Gien","year":"2024","journal-title":"Gynecol Oncol"},{"key":"2026060408361613300_oyag164-B21","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.2217\/imt-2021-0328","article-title":"Complete remission of ovarian clear cell carcinoma achieved after pseudoprogression during PD-1 inhibitor therapy","volume":"14","author":"Ma","year":"2022","journal-title":"Immunotherapy"},{"key":"2026060408361613300_oyag164-B22","doi-asserted-by":"publisher","first-page":"323","DOI":"10.2147\/OTT.S362267","article-title":"Remarkable response to the triplet combination of olaparib with pembrolizumab and bevacizumab in the Third-Line treatment of an ovarian clear cell carcinoma patient with an ARID1A mutation: a case report","volume":"15","author":"Zhao","year":"2022","journal-title":"Onco Targets Ther"},{"key":"2026060408361613300_oyag164-B23","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1136\/ijgc-2022-003430","article-title":"Treatment of ovarian clear cell carcinoma with immune checkpoint blockade: a case series","volume":"32","author":"Sia","year":"2022","journal-title":"Int J Gynecol Cancer"},{"key":"2026060408361613300_oyag164-B24","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.ccell.2018.01.009","article-title":"Eradication of triple-negative breast cancer cells by targeting glycosylated PD-L1","volume":"33","author":"Li","year":"2018","journal-title":"Cancer Cell"},{"key":"2026060408361613300_oyag164-B25","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.1158\/0008-5472.CAN-19-3133","article-title":"Targeting glycosylated PD-1 induces potent antitumor immunity","volume":"80","author":"Sun","year":"2020","journal-title":"Cancer Res"},{"key":"2026060408361613300_oyag164-B26","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1136\/ijgc-2020-001946","article-title":"Risk of second malignancy in patients with ovarian clear cell carcinoma","volume":"31","author":"Nguyen","year":"2021","journal-title":"Int J Gynecol Cancer"},{"key":"2026060408361613300_oyag164-B27","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.ygyno.2022.10.020","article-title":"Molecular portraits of clear cell ovarian and endometrial carcinoma with comparison to clear cell renal cell carcinoma","volume":"169","author":"Ackroyd","year":"2023","journal-title":"Gynecol Oncol"},{"key":"2026060408361613300_oyag164-B28","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13045-018-0693-2","article-title":"Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patients","volume":"12","author":"Tang","year":"2019","journal-title":"J Hematol Oncol"},{"key":"2026060408361613300_oyag164-B29","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-008475","article-title":"Neoadjuvant toripalimab combined with axitinib in patients with locally advanced clear cell renal cell carcinoma: a single-arm, phase II trial","volume":"12","author":"Huang","year":"2024","journal-title":"J Immunother Cancer"},{"key":"2026060408361613300_oyag164-B30","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20201605","article-title":"Tissue-resident memory T cells in tumor immunity and immunotherapy","volume":"218","author":"Ok\u0142a","year":"2021","journal-title":"J Exp Med"},{"key":"2026060408361613300_oyag164-B31","doi-asserted-by":"publisher","first-page":"10619","DOI":"10.7150\/thno.44871","article-title":"CDK4\/6 inhibition promotes immune infiltration in ovarian cancer and synergizes with PD-1 blockade in a B cell-dependent manner","volume":"10","author":"Zhang","year":"2020","journal-title":"Theranostics"},{"key":"2026060408361613300_oyag164-B32","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1517\/14712598.2015.106927","article-title":"Synergy of molecular targeted approaches and immunotherapy in melanoma: preclinical basis and clinical perspectives","volume":"15","author":"Sanlorenzo","year":"2015","journal-title":"Expert Opin Biol Ther"},{"key":"2026060408361613300_oyag164-B33","doi-asserted-by":"publisher","first-page":"7849","DOI":"10.7150\/thno.37218","article-title":"Small molecules as theranostic agents in cancer immunology","volume":"9","author":"Li","year":"2019","journal-title":"Theranostics"},{"key":"2026060408361613300_oyag164-B34","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/nrd4596","article-title":"Big opportunities for small molecules in immuno-oncology","volume":"14","author":"Adams","year":"2015","journal-title":"Nat Rev Drug Discov"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyag164\/68190938\/oyag164.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/6\/oyag164\/68190938\/oyag164.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/6\/oyag164\/68190938\/oyag164.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T12:36:23Z","timestamp":1780576583000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyag164\/8665289"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,28]]},"references-count":34,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,5,8]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyag164","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6]]},"published":{"date-parts":[[2026,4,28]]},"article-number":"oyag164"}}